News that novel T cell–based immunotherapeutic approaches such as immune checkpoint blockade and adoptive cell transfer are achieving durable responses in patients with aggressive cancers has created excitement in the world of cancer research.

It has raised hopes that the body’s immune system may be nimble, potent, and dynamic enough to eradicate tumors despite their ability to mutate and develop resistance, setting the stage for durable responses and cures.

More at Progressnotes, MUSC’s Medical Magazine